Heyuan biological a new drug "rice hematopoiesis" will be applied for clinical trials within this year

On April 27, Wuhan University National Science and Technology Park, in conjunction with Shenzhen investment banking circle, held a docking meeting on venture capital investment and financing in the "self-improvement space" of optical valley Heyuan biological "rice hematopoiesis" project, the world's first road show, sold 5% equity financing of 20 million yuan, and made a full impact on the "new third board" "Rice hematopoiesis" refers to the extraction of human serum albumin from a grain of rice for the treatment of burns and ascites In the past, this kind of albumin can only be extracted from plasma, and the gap is very large Last year, under the leadership of Yang Daichang, chairman of Wuhan Heyuan Biotechnology Co., Ltd and professor of Wuhan University, rice hematopoiesis successfully passed animal tests on rats and cynomolgus monkeys Within this year, it will apply for the clinical approval of national first-class new drugs and carry out human safety tests Yu Dan, financial director of Heyuan bio, said that the R & D and clinical cycle of new drugs is up to 10 years In addition to excellent patent technology, a large amount of investment is needed In 2012, Heyuan biology raised more than 50 million yuan to build a pilot scale-up workshop with a capacity of 1 ton This round of financing is 20 million yuan, which will be mainly used for research and development and application of clinical new drugs Zhou Kai, general manager of Shenzhen investment banking circle, said that for light asset technology enterprises like Heyuan biology, most of their assets are equipment and patents, and the "new third board" is a good capital path for enterprises The financing needs of 8 roadshow enterprises such as Heyuan biology will be financed through the Internet equity crowdfunding platform in the investment banking circle News extension "rice hematopoiesis", the world's first "rice hematopoiesis" in Wuhan, is better than human plasma in some indexes through animal experiments Source: in a grain of rice from Jingchu net, human serum albumin can be extracted for the treatment of burns and ascites In the past, this kind of albumin can only be extracted from plasma, and the gap is very large The reporter yesterday learned from Wuhan Heyuan Biotechnology Co., Ltd., which has mastered the world's leading technology, that the technology passed the preclinical test on the 7th and completed a key step towards human medicine "The experiment was carried out in rats and cynomolgus monkeys The results showed that the human serum albumin extracted from rice had no significant difference in toxicology and pharmacokinetic reaction compared with that extracted from human plasma, and some indexes were even better than that of plasma." Yesterday afternoon, yangdaichang, chairman of Heyuan biology and professor of Wuhan University, presented a report issued by two scientific research institutions with the certification qualification of the State Food and drug administration to the reporter In 2006, Yang Daichang's team began to tackle the "rice hematopoiesis" technology, made breakthrough progress, and obtained a number of patents from China, the United States, Japan and other countries In 2012, the purity of human serum albumin developed by Heyuan bio reached 99.9999%, which is unique in the world Yang Daichang said that it will take another three to five years to enter the clinical application after animal test "For large area burn patients, human serum albumin is a lifesaver!" Xie Weiguo, vice president of Wuhan Third Hospital, said the drug was expensive and often out of stock Data show that human serum albumin is the most widely used blood preparation in the world At present, China's annual clinical demand for human serum albumin is about 210 tons, half of which depends on imports, "rice hematopoiesis" has a broad prospect The entrepreneurial rhythm of Yang Daichang, the father of "rice hematopoiesis": from 99.9% to 99.9999%, there are 3-2 buildings in Zone D of Wuhan Optical Valley Biological city The workers are busy with decoration and the complete set of production equipment has been installed in place "By the end of September, we will have standardized production, so we should hurry up!" Professor Yang Daichang, 60, is surrounded by a group of young people and is hale and hearty In this small building, the world's top "rice hematopoiesis" technology is on its way to industrialization, and a great invention that rewrites the history of Biopharmaceutics is on its way to the world The light yellow liquid rewrites the history in Professor Yang's office The reporter saw the human serum albumin extracted from rice: the light yellow, transparent liquid, contained in a 50ml glass bottle, containing 10g of human serum albumin "For patients with severe cirrhosis, they need to use two bottles a week, and the hospital price is about 500 yuan If the" rice hematopoiesis "technology is used in clinical practice, its price will be greatly reduced." Yang Daichang said According to Yang Daichang, the gene of human serum albumin can be inserted into a certain chromosome position of rice through genetic engineering technology During the growth process, human serum albumin can be automatically synthesized and stored in rice grains through photosynthesis Rice will be shelled, crushed, albumin extracted, repeatedly filtered and purified, freeze-dried Human serum albumin products are produced Human serum albumin extracted from plants has been studied in some countries since 1989, but two major problems are hard to solve: one is that the content of plant synthetic human serum albumin is too low; the other is that it is difficult to extract high-purity products satisfying human body After returning to China in 2006, Yang Daichang led the team to tackle key problems and made breakthrough progress, filling in the gap of large-scale production of this technology in the world, and obtained a number of patents from the United States, Japan and China In 2005, Yang Daichang ran into GUI Hin, an academician of AIDS prevention, on a plane to visit his family Guixi'en mentioned that some poor farmers are suffering from AIDS due to selling blood These illegally purchased blood are often used to extract human serum albumin "Can you try to extract human serum albumin from plant?" Yang Daichang had the idea of returning to China In 2005, he sold his houses and cars in the United States and returned to Wuhan University to take charge of the introduction and basic research of plant biotechnology In 2006, when Yang Daichang's team successfully extracted human serum albumin from rice, he was determined to realize the industrialization of technology But when it comes to "rice hematopoiesis", the industry did not understand or believe that it was difficult to finance the project The project is in the critical stage of the pilot test, and it is in urgent need of capital investment Yang Dai often runs anxiously among experts, peers and competent departments in the industry, inviting them to visit "Some investors, hearing that the project will take at least three or five years to pay off, turn around and leave." Kung Fu is not inferior to those who want it On the eve of the Spring Festival in 2008, Heyuan biology finally obtained 5 million yuan of venture capital Changchun hi tech also extended an olive branch to him, intending to introduce it After hearing the news, the main leaders of the provincial Party Committee immediately gave instructions to "try to ask him to stay." Subsequently, with the full support of the provincial and municipal governments, Yang Daichang's team obtained more than 17 million yuan of financing The dream is becoming a reality in 2011 Yang Daichang's team settled in Guanggu biological city His research achievement "recombinant human serum albumin from plants" has been internationally recognized His paper was published online in the proceedings of the American Academy of Sciences At this time, he became famous He could choose domestic and foreign partners to transfer technology and patents, or he could continue teaching in universities until he retired comfortably However, Yang often chose the most difficult way to start a business Don't mention hardship, just say thanks Yang Daichang said that the provincial and urban areas have customized various policy support for him, also helped to apply for the "Optics Valley 3551 talent plan" and the "one hundred talents plan" of the province, and successfully selected into the seventh batch of "one thousand talents plan" of the state, all of which have won more funds for the company and the project In 2012, after defeating two domestic pharmaceutical giants, "rice hematopoiesis" was selected into the national biomedical "triple" project At that time, the evaluation group composed of academician Sang Guowei and other experts put forward two requirements: to improve the purity of human serum albumin extracted from rice from 99.9% to 99.9999%, and establish a perfect quality control system In order to reach the standard in the shortest time, Yang Daichang and his team worked overtime continuously, reaching 99.9999% in only three months, and established a complete quality assurance system Now, "rice hematopoiesis" has completed pre clinical trials, and will report clinical trials to the State Food and drug administration by the end of this year Yang Daichang's entrepreneurial dream is becoming a reality Yang Daichang was born in 1954 in Xiantao, Hubei Province, professor and doctoral supervisor of School of life sciences, Wuhan University From 1999 to 2005, he worked in California, USA, successively as a scientist, chief scientist and laboratory director of biotechnology company In May 2005, he returned to the school of life sciences, Wuhan University and engaged in the research of rice endosperm cell bioreactor In 2006, he founded Wuhan Heyuan Biotechnology Co., Ltd and served as the chairman of the company
Yang Daichang has been engaged in the research of rice genome and bioreactor technology for a long time During his work in the United States, he has successively obtained 2 U.S patents and 2 U.S international patents After returning to China, he has obtained 2 Chinese patents, applied for 5 patents, obtained 1 U.S patent, 1 Japanese patent, 1 EU patent and 5 international patents After returning to China, he has undertaken 973, 863, major transgenic projects and countries Many projects, such as NSFC, were selected into the fourth batch of talent plan of East Lake high tech Zone 3551, the seventh batch of "thousand talents plan" of the Central Organization Department, and won the second prize of scientific and technological achievements of the Ministry of education in 2009